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MaBACKGROUND The adult mammalian heart is incapable of meaningful regeneration after substantial cardiomyocyte
loss, primarily due to the inability of adult cardiomyocytes to divide. Our group recently showed that mitochondria-
mediated oxidative DNA damage is an important regulator of postnatal cardiomyocyte cell cycle arrest. However, it is not
known whether mechanical load also plays a role in this process. We reasoned that the postnatal physiological increase in
mechanical load contributes to the increase in mitochondrial content, with subsequent activation of DNA damage
response (DDR) and permanent cell cycle arrest of cardiomyocytes.
OBJECTIVES The purpose of this study was to test the effect of mechanical unloading on mitochondrial mass, DDR, and
cardiomyocyte proliferation.
METHODS We examined the effect of human ventricular unloading after implantation of left ventricular assist devices
(LVADs) on mitochondrial content, DDR, and cardiomyocyte proliferation in 10 matched left ventricular samples collected
at the time of LVAD implantation (pre-LVAD) and at the time of explantation (post-LVAD).
RESULTS We found that post-LVAD hearts showed up to a 60% decrease in mitochondrial content and up to a 45%
decrease in cardiomyocyte size compared with pre-LVAD hearts. Moreover, we quantiﬁed cardiomyocyte nuclear foci of
phosphorylated ataxia telangiectasia mutated protein, an upstream regulator of the DDR pathway, and we found a
signiﬁcant decrease in the number of nuclear phosphorylated ataxia telangiectasia mutated foci in the post-LVAD hearts.
Finally, we examined cardiomyocyte mitosis and cytokinesis and found a statistically signiﬁcant increase in both phos-
phorylated histone H3–positive, and Aurora B–positive cardiomyocytes in the post-LVAD hearts. Importantly, these
results were driven by statistical signiﬁcance in hearts exposed to longer durations of mechanical unloading.
CONCLUSIONS Prolonged mechanical unloading induces adult human cardiomyocyte proliferation, possibly through
prevention of mitochondria-mediated activation of DDR. (J Am Coll Cardiol 2015;65:892–900) © 2015 by the American
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893and is thought to result from functional recovery of
viablemyocardiumdue to a combination of ventricular
unloading and pharmacological therapy (13).SEE PAGE 901
DDR = DNA damage response
LVAD = left ventricular
assist device
mtDNA = mitochondrial DNA
pATM = phosphorylated ataxia
telangiectasia mutated protein
PBS = phosphate-buffered
saline
pH3 = phosphorylated
histone H3
ROS = reactive oxygen speciesOur group recently showed that activation of the
DNA damage response (DDR) is an important mecha-
nism of cell cycle arrest in postnatal mammalian
cardiomyocytes (14). We showed that the buildup of
mitochondrial mass postnatally results in increased
reactive oxygen species (ROS) production, oxidative
DNA damage, and activation of DDR. Although the
relative hyperoxemia of the postnatal heart plays an
important role in up-regulation of oxidative meta-
bolism, increased mechanical load is also known to
activate cardiac mitochondrial biogenesis (15). We
therefore reasoned that mechanical unloading might
reverse the metabolic cascade that results in cell cycle
arrest of cardiomyocytes. In this respect, human LVAD
hearts provide the unique opportunity to perform
histological analysis in the same patient in 2 drastically
variable physiological states. We conducted this study
to test the effect of mechanical unloading on mito-
chondrial mass, DDR, and cardiomyocyte proliferation
in patients who received LVADs.
METHODS
PATIENT SAMPLES. Humanheart tissue sampleswere
obtained from patients with advanced heart failure
after informed consent under 2 overlapping institu-
tional review board protocols approved by the UT
Southwestern Medical Center Clinical Institutional
Review Board Committee (Institutional Review Board
#STU 092010-193 and #STU 092010-093). The patients
had been referred to the UT Southwestern Medical
Center Heart Failure, Ventricular Assist Device & Heart
Transplant Program for consideration of either im-
plantation of an LVAD and/or a heart transplantation.
Paired heart tissue samples were obtained from
each patient: ﬁrst at the time of LVAD implantation
and again at the time of heart transplantation.
Pre-LVAD samples were acquired from the left ven-
tricular apex, whereas the post-LVAD samples were
obtained from the lateral wall of the left ventricle.
Once the left ventricular tissue was removed from the
patient, the tissue was either ﬁxed for 48 h in 10%
formalin or snap-frozen in liquid nitrogen. The ﬁxed
tissue samples were submitted to the UT South-
western Medical Center Cardiovascular Histological
Laboratory for parafﬁn embedding and processing for
various immunohistological studies.
MITOCHONDRIAL DNA QUANTIFICATION BY REAL-TIME
POLYMERASE CHAIN REACTION. For mitochondrialDNA (mtDNA) quantiﬁcation, DNA was ex-
tracted and puriﬁed from tissue samples
with proteinase K digestion and subsequent
phenol/chloroform extraction. mtDNA was
quantiﬁed with real-time polymerase chain
reaction with the following primers: mtDNA F:
CTAAATAGCCCACACGTTCCC; R: AGAGCTCC
CGTGAGTGGTTA (targeting a relatively stable
site in mitochondrial DNA minimal arc [16]),
and nuclear DNA F: GCTGGGTAGCTCTAAA
CAATGTATTCA; R: CCATGTACTAACAAATGTC
TAAAATGGT (targeting single-copy nuclear
DNA within the beta-2M gene [16]), using SYBR
Green PCR Master Mix and the 7000 Sequence
Detection System (Applied Biosystems, Foster City,
California). The relative mtDNA copy number was
calculated from the ratio of mtDNA copies to nuclear
DNA copies per gram of tissue. The relative fold change
was then calculated using the DDCT method.
PROTEIN EXTRACTION FROM HEART TISSUE AND
WESTERN BLOTTING. Whole-cell extracts from hu-
man heart samples were prepared as described pre-
viously (14). Brieﬂy, samples were homogenized in
radioimmunoprecipitation assay buffer using a hand-
held homogenizer (Thermo Fisher Scientiﬁc, Wal-
tham, Massachusetts) on ice for 30 min. Cell extracts
were centrifuged at 14,000 rpm for 30 min at 4C to
remove insoluble material. Radioimmunoprecipita-
tion assay buffer contained phenylmethylsulfonyl
ﬂuoride, aprotinin (1 mg/ml), leupeptin (1 mg/ml),
pepstatin A (1 mg/ml), sodium ﬂuoride (150 mM),
and sodium metavandate (1 mM). Aliquots con-
taining 200 mg protein were resolved by 8% sodium
dodecylsulfate–polyacrylamide gel electrophoresis
and then transferred onto nitrocellulose membrane at
30 V at 4C overnight. Membranes were blocked with
5% milk in Tris-buffered saline–0.1% Tween 20) at
room temperature for 20 min and incubated with
different antibodies in 5% milk in Tris-buffered
saline–0.1% Tween 20 at 4C overnight. Membranes
were subsequently washed 3 times for 5 min each
with Tris-buffered saline–0.1% Tween 20, and then
incubated with horseradish peroxidase–conjugated
secondary antibodies (anti-mouse/rabbit/goat) in 5%
milk for 2 h at room temperature. The primary anti-
bodies used for Western blotting were as follows:
phosphorylated ataxia telangiectasia mutated (pATM)
protein; 10H11.E12) (sc-47732, mouse, 1:500, Santa
Cruz Biotechnology, Dallas, Texas) and cardiac
troponin T (13-11, mouse, 1:10,000, Thermo Fisher
Scientiﬁc, Richardson, Texas). Quantiﬁcation analysis
of the Western blot signal was done using ImageJ
(National Institutes of Health, Bethesda, Maryland).
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894IMMUNOSTAINING. Samples for immunostaining were
prepared as described previously (14). Brieﬂy, after
antigen retrieval with 1 mM ethylenediamine tetraacetic
acid containing 0.05% Tween in boiling water, sections
were blocked with 10% serum from the secondary anti-
body host animal and 0.3% Triton-X100, and incubated
with primary antibodies overnight at 4C. Sections were
subsequently washed with phosphate-buffered saline
(PBS) and incubated with corresponding secondary an-
tibodies conjugated to Alexa Fluor 488 or 555 (Life
Technologies, Carlsbad, California). Primary antibodies
used were as follows: anti–phosphorylated histone
H3 (pH3); Ser10 (#06-570, 1:100, Millipore, Billerica,
Massachusetts); anti–Aurora B (A5102, 1:25, Sigma, St.
Louis, Missouri); anti–troponin T, Cardiac Isoform Ab-1,
Clone 13-11 (MS-295-P1, 1:100, Thermo Fisher Scien-
tiﬁc); anti–sarcomeric alpha-actinin (ab68167, 1:100,
Abcam, Cambridge, Massachusetts); and anti-pATM
(sc-47739, 1:100, Santa Cruz Biotechnology).
CELL SIZE—WHEAT GERM AGGLUTININ STAINING.
After antigen retrieval, slides were rinsed 3 times in
PBS and then incubated overnight at 4C with
troponin T antibody. The following day, the slides
were rinsed 3 times with PBS and incubated for 1 h at
room temperature with a primary antibody against
wheat germ agglutinin conjugated to 50 mg/ml Alexa
Fluor 488 (Life Technologies) and secondary antibody
for troponin T. Slides were then rinsed in PBS and
mounted in Vectashield (Vector Laboratories, Bur-
lingame, California). To quantify cell size, images at
20were captured, and ImageJ (National Institutes of
Health) was used to determine the area of each cell.
Quantitative analyses involved the counting of mul-
tiple ﬁelds from 3 independent samples per group
(w50 cells per ﬁeld assessed, total w250 cells per
group).
IMAGE ACQUISITION AND pATM FOCI QUANTIFICATION.
Analysis and quantiﬁcation of pATM were per-
formed of images captured by a high-resolution LSM
510 Meta laser scanning confocal microscope (Carl
Zeiss Inc., Thornwood, New York) equipped with a
63 1.4 NA Plan-Apochromat oil immersion objective
(Carl Zeiss Inc.). Images were taken at z-sections
(24 sections) at 0.35-mm intervals using the 488 nm
(Alexa 488, Life Technologies), 543 nm (Alexa
555, Life Technologies) and 405 nm (for 2-[4-
amidinophenyl]-1H-indole-6-carboxamidine) lasers.
The tube current of the 488-nm argon laser was set at
6.1 Å. The laser power was typically set at 3% to 5%
transmission with the pinhole opened to 1 to 2 Airy
units. The z-sections were subsequently assembled
using Imaris software (Bitplane, South Windsor,
Connecticut) and then used for further analysis. Tocount pATM foci, we used the spot detection function
of the Imaris software, which determined the spatial
position along the x-axis, y-axis, and z-axis and the
intensity of the pATM focus that the spot represents.
We conﬁrmed the accuracy of foci counting using the
same software’s colocalization function and observed
>99% colocalization of the detected spots with pATM
foci. For each sample, the average number of foci per
myocyte was quantiﬁed for images of 10 to 13 ﬁelds.
IMAGE ACQUISITION FOR pH3 QUANTIFICATION.
Analysis and quantiﬁcation of pH3-positive cells were
performed using ﬂuorescent microscopy and high-
resolution confocal microscopy as described in the
preceding section. Only cells displaying a positive
pH3 signal in the nucleus, with z-stacking–conﬁrmed
2-(4-amidinophenyl)-1H-indole-6-carboxamidine and
actinin colocalization in the same cell were counted.
Mitotic cardiomyocytes were counted only if a pH3-
positive nucleus was entirely within the boundaries of
an actinin-positive cell as determined by continuous
actinin staining surrounding the nucleus. False-positive
cells with unclear colocalization of pH3 with either 2-(4-
amidinophenyl)-1H-indole-6-carboxamidine or actinin
or with punctate pH3 staining were excluded.
STATISTICAL ANALYSIS. Pre- and post-LVAD sam-
ples were compared using the paired Student t test.
To assess the impact of dependence on the assump-
tion of normality, a sensitivity analysis was per-
formed using the nonparametric Wilcoxon signed
rank test for matched pairs. Results of the nonpara-
metric sensitivity analyses were similar to those of
the primary analyses for all comparisons (data not
shown). On the basis of previous research suggesting
a lack of change in myocardial viability with short
(2 to 3 months) LVAD duration (17), an a priori strat-
iﬁcation was performed at an LVAD duration of
6 months or less (group 1, short LVAD duration)
versus longer than 6 months (group 2, long LVAD
duration). Results are expressed as mean  SEM.
Statistical analyses were performed using SAS version
9.2 (SAS Institute, Cary, North Carolina). All statistical
tests were 2-tailed with p < 0.05 considered statisti-
cally signiﬁcant.
RESULTS
This study included 10 patients (3 female and 7 male)
from whom we were able to collect matched tissue
samples pre- and post-LVAD at the time of heart
transplantation. The average age of these patients
was 51 years, and 2 of the patients have since
died. The etiology of cardiomyopathy included non-
ischemic, ischemic, familial, and chemotherapy-
induced cardiomyopathies. The duration of left
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895ventricular mechanical unloading with the LVAD
ranged from 1 to 25 months (Figure 1A). Quantiﬁcation
was performed on the entire population, as well as on
groups 1 and 2.
To test the effect of mechanical unloading with an
LVAD on cardiomyocyte mitochondrial content, we
analyzed mtDNA in ventricular chambers with or
without LVAD support. Quantitative real-time poly-
merase chain reaction analysis of mtDNA copy num-
ber standardized to nuclear DNA copy number in
post-LVAD tissue samples showed a decrease of up
to 60% compared with matched pre-LVAD samples
(n ¼ 10) (Central Illustration A, Figure 1B). Interest-
ingly, heart failure patients maintained on LVADs for
longer than 6 months (group 2) (Figure 1B) showed a
greater decrease in mtDNA content compared with
patients with LVADs for less than 6 months (group 1)FIGURE 1 LVAD Support for Heart Failure Patients Leads to Decreas
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sively decreases with longer LVAD duration.
We then examined the effect of ventricular
unloading on cardiomyocyte size. To test this, we
performed anti–wheat germ agglutinin staining to
visualize cardiomyocyte boundaries and to facilitate
measurement of cardiomyocyte cell size (Central
Illustration B, Figure 1C, Online Figure S3A). A
decrease of as much as 45% in cardiomyocyte cell size
in post-LVAD ventricles compared with pre-LVAD
ventricles was observed, suggesting that ventricular
unloading can reverse cardiomyocyte hypertrophy in
the human heart. Consistent with the effect of longer
LVAD duration on reduction of mitochondrial mass, a
statistically signiﬁcant decrease in cardiomyocyte
size was only observed in patients with LVADs for
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CENTRAL ILLUSTRATION Cardiomyocyte Proliferation in LVAD Patients: Prolonged Mechanical Unloading Results in a
Switch From Hypertrophic to Hyperplastic Cardiomyocyte Growth
Both mtDNA content (A) and cell size (B) markedly decreased post-LVAD in the combined samples. The DNA damage response was not signiﬁcantly
decreased in the combined samples post-LVAD, as shown by measurements of pixels/area (C) and by the number of pATM protein foci per myocyte in the
combined samples. Post-LVAD, cardiomyocyte mitosis, shown by increased pH3-positive cardiomyocytes (D), and cardiomyocyte cytokinesis, shown by
increased Aurora B localization to cytokinetic furrows (E), were both signiﬁcantly increased in the combined samples. Collectively, these results
suggest that mechanical unloading results in cardiomyocyte cell cycle re-entry. LVAD ¼ left ventricular assist device; mtDNA ¼ mitochondrial DNA;
pATM ¼ phosphorylated ataxia telangiectasia mutated protein; PH3 ¼ phosphorylated histone H3.
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896As we previously showed (14), reduced mtDNA
content is suggestive of lower mitochondrial ROS level
and, as a consequence, reduced oxidative DNA dam-
age. Importantly, due to signiﬁcant variability in
timing of access to tissue samples (investigators did
not have immediate access to tissue at the time of
harvesting), measuring ROS was not feasible in these
human samples. We hypothesized that ventricularunloading reduces activation of the DDR, which we
previously found to be an important mediator of car-
diomyocyte cell cycle arrest (14). To examine the acti-
vation of the DDR in cardiomyocytes of pre-LVAD or
post-LVAD hearts, we used immunoﬂuorescence and
high-resolution confocal microscopy to quantify nu-
clear pATM (Central Illustration C, Figure 2, Online
Figure S3B), which is recruited to DNA lesion foci and
FIGURE 2 LVAD-Mediated Pressure Unloading Leads to Reduced DDR in Adult Human Cardiomyocytes
pATM α-Actinin DAPI Merged
Pre-LVAD
Post-LVAD
Pre-LVAD
Post-LVAD
pATM α-Actinin DAPI Merged
pA
TM
 F
oc
i P
er
 M
yo
cy
te
210 p=0.232
p=0.400 p=0.025
140
70
0
210
140
70
0
Combined
Samples
Group 1 Group 2
pA
TM
 F
oc
i P
er
 M
yo
cy
te
Pre-LVAD
Post-LVAD
Representative Images for Group 1 (Patient 12) Representative Images for Group 2 (Patient 85)
10um
High-resolution confocal microscopy of immunostaining with pATM antibody shows a signiﬁcant decrease in nuclear pATM foci and the DDR only in longer duration
group 2 post-LVAD cardiomyocytes. DAPI ¼ 2-(4-amidinophenyl)-1H-indole-6-carboxamidine; DDR ¼ DNA damage response; LVAD ¼ left ventricular assist device;
pATM ¼ phosphorylated ataxia telangiectasia mutated protein.
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897acts as an upstream regulator of the DDR pathway (18).
Although cardiomyocytes of patients with shorter
durations of LVAD (group 1) did not show a statistically
signiﬁcant difference in the number of nuclear pATM
foci, cardiomyocytes from patients with longer dura-
tions of LVAD (group 2) showed a signiﬁcant decrease
in the number of nuclear pATM foci, indicating that
the DDR is deactivated after prolonged ventricular
unloading (Figure 2). These ﬁndings were also sup-
ported by quantitative Western blot analysis, which
revealed a trend toward down-regulation of pATM
levels in protein extracts from hearts with longer
LVAD durations (Online Figures S1A and S3C).
However, this analysis did not reach statistical
signiﬁcance, likely due to inclusion of noncardio-
myocytes in the protein extract (compared with
the more speciﬁc quantiﬁcation of pATM foci in
cardiomyocyte nuclei).
When mammalian cardiomyocytes exit the cell
cycle postnatally, they display an increase in mito-
chondrial mass, cell size, and DDR activation (14), all
of which are decreased after long-term unloading, as
described earlier. Therefore, we next tested whether
pressure unloading reverses cardiomyocyte cell cycle
arrest. We examined cardiomyocyte mitosis by im-
munostaining using anti-pH3 Ser 10, a speciﬁc marker
of G2-M progression. Quantiﬁcation of the number
of cardiomyocytes with nuclear pH3 signal (Central
Illustration D, Figure 3A, upper panels) revealed a sta-
tistically signiﬁcant increase in pH3-positive car-
diomyocytes in all post-LVAD patients combined. This
increase was not signiﬁcant in shorter duration LVAD
patients (group 1), consistent with the lack of an
appreciable decrease in pATM foci in these car-
diomyocytes. However, the number of pH3-positivecardiomyocytes was signiﬁcantly increased in
patients with longer LVAD duration (group 2)
(Figure 3A, Online Figure S3D). It is important to note
that myocyte proliferation was conﬁrmed by stringent
criteria, using high-resolution confocal z-stacking mi-
croscopy, the gold standard method for identiﬁcation
of cardiomyocyte nuclei (Figure 3A, upper panels).
These ﬁndings were further supported by quantiﬁca-
tion of the localization of the cytokinesis marker
Aurora B kinase to the cleavage furrow between 2 car-
diomyocytes (19) (representative images of all samples
examined in this study are shown in Online Figure S2).
Quantiﬁcation of confocal images indicated a signiﬁ-
cant increase of Aurora B–positive cells in all post-
LVAD samples combined, with a similar statistically
signiﬁcant increasewith longer LVADduration (Central
Illustration D, Figure 3B, Online Figures 2 and 3E).
It is important to note here that we also used strict
z-stack quantiﬁcationwithout the use of 2-dimensional
imaging. This was necessary because Aurora B can be
found in the cleavage furrow between 2 myocytes that
are not necessarily in the same horizontal plane
(as demonstrated in the ﬁgure inset). This technique
markedly increased the sensitivity and speciﬁcity of
identifying true cardiomyocyte cytokinesis. Collec-
tively, these results indicate that ventricular unload-
ing, especially for longer durations, induces cell cycle
re-entry in adult human cardiomyocytes.
DISCUSSION
Cell cycle re-entry of mammalian adult cardio-
myocytes has been previously demonstrated in ani-
mal models (20–25); however, similar ﬁndings have
not been reported in humans because of the difﬁculty
FIGURE 3 LVAD-Mediated Pressure Unloading Induces Cardiomyocyte Proliferation in Adult Human Heart
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898of performing such studies. The current study builds
on our recent work (14), which suggested that car-
diomyocyte cell cycle exit is a regulated process and
likely to play a protective role against replication inthe setting of oxidative DNA damage. We previously
demonstrated that, by enhancing mitochondrial ROS
production and oxidative DNA damage, the postnatal
hyperoxic environment is an important mediator of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Mechanical
unloading of the human heart decreases the size of cardiomyo-
cytes and mitochondrial content and, when prolonged, induces
cardiomyocyte proliferation through DNA damage response-
dependent effects on the cell cycle.
TRANSLATIONAL OUTLOOK: Additional studies are needed
to explore the regenerative effects on the myocardium of pro-
longed mechanical unloading.
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899cardiomyocyte cell cycle exit. We now show that
mechanical loading is an important regulator of
mitochondrial biogenesis, DDR, and cardiomyocyte
cell cycle in the adult human heart. Importantly,
although the effects of mechanical unloading on
cardiomyocyte size and nucleation were previously
described (10,12,26), the current study indicates that
the reverse remodeling that occurs with unloading
may represent a switch from hypertrophic to hyper-
plastic growth. The current study highlights the
association between the duration of LVAD mechanical
support and molecular changes in cardiomyo-
cytes, where decreased DDR and induction of
cardiomyocyte proliferation were restricted to longer
LVAD durations. Consistent with these observations,
a recent study showed no post-LVAD change in
myocardial viability after a short duration on LVAD,
highlighting the need for a better understanding of
the temporal effects of mechanical unloading on
cardiomyocyte cell cycle and heart regeneration (17).
The current ﬁndings are consistent with those of
previous reports suggesting that functional recovery
on an LVAD may be possible (4,27,28), although var-
iations in protocol, duration on LVAD, and outcomes
highlight the need for in-depth examination of
myocardial viability and contractile function after
mechanical unloading.
STUDY LIMITATIONS. Despite the signiﬁcance of
these ﬁndings, the current study falls short of
providing a clear understanding of the mechanism of
cell cycle entry after mechanical unloading. Other
limitations also include the small sample size, in
particular in group 1, and the difference in anatomic
location of pre-LVAD and post-LVAD samples (apex
and lateral wall, respectively). More importantly,
although there is clear evidence of cardiomyocyte
proliferation in the unloaded human heart, it is un-
clear whether this leads to an appreciable regenera-
tive effect and restores contractile function in the
failing heart. Certainly, any attempts at reloadingpost-LVAD ventricles must take into account the
signiﬁcant cardiomyocyte atrophy that occurs after
prolonged mechanical unloading, which will likely
hamper any appreciable restoration of cardiac output
without reactivation of cardiomyocyte hypertrophy.
CONCLUSIONS
Prolonged mechanical unloading of the human heart
results in a switch from hypertrophic to hyperplastic
cardiomyocyte growth.
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